AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

The most advanced weight loss candidate in Novo Nordisk’s pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy.

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and type 2 diabetes patients. Read more here.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Mike Vaccaro Leon Rose upgrading Knicks depth chart comes with dose of Tom Thibodeau ‘irony’ By Mike Vaccaro Published July 1, 2025, 7:58 p.m. ET ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from ...

The high-dose influenza vaccine elicits stronger immune responses in immunocompromised patients while maintaining a safety profile similar to that of the standard-dose vaccine, a meta-analysis shows.